This work, conducted by researchers from Denmark and Norway, has compared national rates of blood clots and related conditions after vaccination with AstraZeneca with those of the general population in both countries. Specifically, their results are based on 280,000 people between the ages of 18 and 65 who received a first dose of the vaccine in Denmark and Norway from February 2021 to March 11.
Analysis of the data found 59 blood clots in the veins compared to the expected 30, corresponding to an excess of 11 events per 100,000 vaccinations. This included a higher than expected rate of blood clots in the brain, known as cerebral venous thrombosis (2.5 events per 100,000 vaccinations). However, they did not find an increase in the rate of arterial clots, such as heart attacks or strokes.
Despite the trend registered, the authors emphasize that the absolute risks of venous thromboembolic events described are small , and that the results should be interpreted in the context of the benefits of vaccination against Covid-19 both at the social and at the social level. individual. In addition, they explain that the study carried out is observational, so it cannot establish a cause, but only a correlation.
Denmark and Norway have suspended vaccination with AstraZeneca
Denmark and Norway are two of the European countries that have suspended vaccination with AstraZeneca doses. The first has done it indefinitely and has included the Janssen vaccine, which also has thrombosis as a rare side effect. And the second, has postponed the decision to continue with AstraZeneca until next May 10.
Both countries agree with the European Medicines Agency that the serum developed by Oxford is safe. However, the balance between risk and benefit is modulating according to the state of the pandemic and the number of people at risk vaccinated.
